SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?


To: celeryroot.com who wrote (1637)9/1/1999 12:42:00 PM
From: Doorman  Respond to of 2173
 
Hi Celery,

This is one analyst's opinion comparing the trials:

Mehta Partners pharmaceuticals analyst Tom Brakel
told Reuters: "Symlin apparently got better results this time around compared with earlier trials because the newest studies were
designed to make sure patients took more consistent doses of insulin."